You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AKT 2 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 10, 2022

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +4 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +6 more
Jan 13, 2022

Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 25, 2023

Bile Acids in Acute Insulin Resistance

Recruiting
  • PI3K Gene Mutation
  • +4 more
  • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
  • New York, New York
    Columbia University Medical Center
Oct 6, 2022

Estrogen Receptor Positive Breast Cancer Trial in United Kingdom (AZD5363, Placebo, Fulvestrant)

Active, not recruiting
  • Estrogen Receptor Positive Breast Cancer
  • Manchester, Greater Manchester, United Kingdom
  • +20 more
Aug 5, 2022

Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

Recruiting
  • Metastatic Breast Cancer
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic

Not yet recruiting
  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • (no location specified)
Sep 13, 2022

Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

Recruiting
  • Premenopausal Breast Cancer
  • +2 more
  • Taipei City, Taiwan
    Department of Oncology, National Taiwan University Hospital
Feb 7, 2023

CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,

Terminated
Has Results
  • Central Nervous System Lymphoma
  • +6 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 30, 2022

Breast Cancer Trial in Boston (Ipatasertib, Fulvestrant, Aromatase Inhibitor)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Oct 25, 2021

Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis Trial in United States (procedure, drug,

Not yet recruiting
  • Colorectal Adenomatous Polyp
  • +3 more
  • Biopsy
  • +5 more
  • Ann Arbor, Michigan
  • +4 more
Jan 3, 2023

Breast Cancer, Prostate Cancer, Advanced Solid Tumors Trial in Middletown, Harrison, New York (AZD5363, Enzalutamide,

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Middletown, New Jersey
  • +2 more
Jul 5, 2022

Triple Negative Breast Cancer Trial in Madison (Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet)

Terminated
Has Results
  • Triple Negative Breast Cancer
  • Akt/ERK Inhibitor ONC201
  • Methionine-Restricted Diet
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Feb 11, 2022

Everolimus-containing Chemotherapy in HER2- mBC PI3K/AKT/mTOR

Completed
  • Breast Cancer
  • +2 more
  • No intervention, it was a retrospective study.
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 13, 2021

Seborrheic Keratosis Trial in Santa Tecla (SM-020)

Recruiting
  • Seborrheic Keratosis
  • Santa Tecla, La Libertad, El Salvador
    Zepeda Dermatologia
Aug 20, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial (Biopsy,

Not yet recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Nov 8, 2022

Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • (no location specified)
Oct 31, 2023

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma Trial in Houston (L-NMMA)

Recruiting
  • HER2-negative Breast Cancer
  • +3 more
  • Houston, Texas
    Houston Methodist Neal Cancer Center
Jan 12, 2023

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Breast Cancer Trial (GSK3326595)

Completed
  • Breast Cancer
  • London, Ontario, Canada
    St. Joseph's Health Care London
Oct 24, 2022

Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)

Active, not recruiting
  • Metastatic Breast Cancer
  • PARP inhibitor 2X-121
  • Herlev, Denmark
  • +1 more
Feb 1, 2023

Compare Overall Survival in Medicare Metastatic Breast Cancer

Active, not recruiting
  • Breast Cancer
  • New York, New York
    Pfizer New York
Oct 11, 2023